

PARTICULARS TO APPEAR ON THE OUTER PACKAGE Carton

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Cephacare flavour 500 mg tablets for dogs

2. STATEMENT OF ACTIVE SUBSTANCES

Each tablet contains 500 mg cefalexin as cefalexin monohydrate.

3. PACKAGE SIZE

20 tablets
100 tablets
250 tablets

4. TARGET SPECIES

Dogs.

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Oral use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}
Return any ½ tablet to the blister and use within 24 hours.

9. SPECIAL STORAGE PRECAUTIONS

Do not store above 25 °C.
Keep the blister in the outer carton.
Store in a dry place.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER



14. MARKETING AUTHORISATION NUMBER

Vm 32742/4030

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING
UNITS Blister

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Cephacare flavour 500 mg tablets for dogs

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Each tablet contains 500 mg cefalexin.

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Cephacare flavour 500 mg tablets for dogs

2. Composition

Each tablet contains:

Active substance:

Cefalexin (as cefalexin monohydrate) 500 mg

Beige speckled, flat tablets with a break mark on one side.

3. Target species

Dogs.

4. Indications for use

Treatment of infections of the respiratory tract, gastrointestinal tract, urogenital tract, the skin and localised infections in soft tissue caused by bacteria sensitive to cefalexin.

5. Contraindications

Do not use in cases of hypersensitivity to the active substance, to other cephalosporins, to other substances of the β -lactam group or to any of the excipients. Do not use in rabbits, gerbils, guinea pigs and hamsters.

6. Special warnings

Special precautions for safe use in target species:

Use of the veterinary medicinal product should be based on susceptibility testing and take into account official and local antimicrobial policies.

Use of the veterinary medicinal product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to cefalexin and may

decrease the effectiveness of treatment with penicillins, due to the potential for cross-resistance.

In the case of an allergic reaction, treatment should be withdrawn.

As with other antibiotics which are excreted mainly by the kidneys, unnecessary accumulation may occur in the body when renal function is impaired. In cases of known renal insufficiency, the dose should be reduced, antimicrobials known to be nephrotoxic should not be administered concurrently and the veterinary medicinal product should be used only according to the benefit-risk assessment by the responsible veterinarian.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillin may lead to cross-reactions to cephalosporin and vice versa. Allergic reactions to these substances may occasionally be serious.

- People with known hypersensitivity to cefalexin should avoid contact with the veterinary medicinal product.
- Handle this veterinary medicinal product with great care to avoid exposure, taking all recommended precautions.
- If you develop symptoms following exposure such as skin rash you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty breathing are more serious symptoms and require urgent medical attention.
- In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
- Wash hands after use.

Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy or lactation. Use only according to the benefit-risk assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:

The bactericidal activity of cephalosporins is reduced by concomitant administration of bacteriostatic acting compounds (macrolides, sulphonamides and tetracyclines). Nephrotoxicity can be increased when 1st generation cephalosporins are combined with polypeptide antibiotics, aminoglycosides and some diuretics (furosemide). Concomitant use with such active substances should be avoided.

Overdose:

The administration of cefalexin has been shown to produce no serious side effects at many times the recommended dose rate.

7. Adverse events

Dogs:

Rare (1 to 10 animals / 10,000 animals treated):	Hypersensitivity*
Undetermined frequency (cannot be estimated from the available data):	Diarrhoea**, vomiting**

*When observed, the treatment should be discontinued and occurring symptoms should be treated symptomatically.

**When observed, treatment should be stopped and the advice of the attending veterinarian should be sought.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

e-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

Oral use. A dose of 15 mg/kg twice daily is recommended, to be doubled where appropriate.

9. Advice on correct administration

The veterinary medicinal product has a break mark on one side. To enable more accurate dosing, half tablets may be used as necessary.

Treatment for five days is recommended. Any increase in dose or duration of use should be according to the benefit-risk assessment by the responsible veterinarian (e.g. in cases of chronic pyoderma).

Tablets may be added to food if necessary.

To ensure a correct dosage, body weight should be determined as accurately as possible.

The use of cefalexin tablets of lower strengths is advised for dogs with lower body weights.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

Return any ½ tablet to the blister and use within 24 hours.

Keep the blister in the outer carton.

Do not store above 25 °C.

Store in a dry place.

Do not use this veterinary medicinal product after the expiry date which is stated on the blister and carton after Exp. The expiry date refers to the last day of that month.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

Vm 32742/4030

The veterinary medicinal product is supplied in packs of 20, 100 or 250 tablets.

Not all pack sizes may be marketed.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder:

Ecuphar NV
Legeweg 157-i
8020 Oostkamp
Belgium

Manufacturers responsible for batch release:

Lelypharma B.V.
Zuiveringweg 42
8243 PZ
Lelystad
The Netherlands

Produlab Pharma B.V.
Forellenweg 16
4941 SJ
Raamsdonksveer
The Netherlands

Local representatives and contact details to report suspected adverse reactions:

Animalcare Ltd.
Moorside
Monks Cross
York
YO32 9LB, UK
Tel: +44 (0) 330 8189717
E-mail: animalcare@animalcare.co.uk

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

17. Other information

POM-V

Gavin Hall
Approved: 13 August 2025